Kidswell Bio Corp. (4584) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Kidswell Bio Corp.

GNI Group Ltd.

OncoTherapy Science, Inc.

Cyfuse Biomedical KK

MEDINET Co., Ltd.

SUSMED, Inc.

Stella Pharma Corp.

Oncolys BioPharma, Inc.

Chiome Bioscience, Inc.

StemCell Institute

Carna Biosciences, Inc.

Why is Kidswell Bio Corp. ?

The company has declared Positive results for the last 3 consecutive quarters

PRE-TAX PROFIT(Q) At JPY 175.62 MM has Grown at 882.24%
NET PROFIT(Q) At JPY 157.13 MM has Grown at 2,384.8%
ROCE(HY) Highest at 22.64%

With ROE of -1.95%, it has a risky valuation with a 7.40 Price to Book Value

Over the past year, while the stock has generated a return of 78.81%, its profits have risen by 98%

Market Beating Performance

The stock has generated a return of 78.81% in the last 1 year, much higher than market (Japan Nikkei 225) returns of 28.54%

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Kidswell Bio Corp. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Kidswell Bio Corp. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Kidswell Bio Corp.

78.81%

0.63

96.28%

Japan Nikkei 225

28.54%

1.11

25.75%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

36.37%

EBIT Growth (5y)

15.14%

EBIT to Interest (avg)

-34.17

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.82

Sales to Capital Employed (avg)

1.06

Tax Ratio

100.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

2.20%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.40

EV to EBIT

332.98

EV to EBITDA

322.57

EV to Capital Employed

36.62

EV to Sales

1.83

PEG Ratio

Dividend Yield

ROCE (Latest)

11.00%

ROE (Latest)

-1.95%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

35What is working for the Company

PRE-TAX PROFIT(Q)

At JPY 175.62 MM has Grown at 882.24%

NET PROFIT(Q)

At JPY 157.13 MM has Grown at 2,384.8%

ROCE(HY)

Highest at 22.64%

INVENTORY TURNOVER RATIO(HY)

Highest at 3.8%

NET SALES(Q)

At JPY 1,720.63 MM has Grown at 35.43%

OPERATING PROFIT(Q)

Highest at JPY 184.71 MM

CASH AND EQV(HY)

Highest at JPY 5,835.51 MM

DEBT-EQUITY RATIO (HY)

Lowest at -63.06 %

OPERATING PROFIT MARGIN(Q)

Highest at 10.74 %

-1What is not working for the Company

RAW MATERIAL COST(Y)

Grown by 25.58% (YoY

Here's what is working for Kidswell Bio Corp.

Pre-Tax Profit

At JPY 175.62 MM has Grown at 882.24%

over average net sales of the previous four periods of JPY 17.88 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (JPY MM)

Net Profit

At JPY 157.13 MM has Grown at 2,384.8%

over average net sales of the previous four periods of JPY -6.88 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (JPY MM)

Net Sales

At JPY 1,720.63 MM has Grown at 35.43%

over average net sales of the previous four periods of JPY 1,270.51 MM

MOJO Watch

Near term sales trend is very positive

Net Sales (JPY MM)

Operating Profit

Highest at JPY 184.71 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (JPY MM)

Inventory Turnover Ratio

Highest at 3.8% and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Operating Profit Margin

Highest at 10.74 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Cash and Eqv

Highest at JPY 5,835.51 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -63.06 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Kidswell Bio Corp.

Raw Material Cost

Grown by 25.58% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales